abbrevi
ctb
cholera
toxin
b
subunit
etec
enterotoxigen
escherichia
coli
fda
food
drug
administr
fmdv
foot
mouth
diseas
viru
hbsag
hepat
b
surfac
antigen
ltb
heatlabil
toxin
etec
b
subunit
mv
measl
viru
tgev
transmiss
gastroenter
coronaviru
tmv
tobacco
mosaic
viru
tsp
total
solubl
protein
wwwcurrentopinioncom
amanda
walmsley
charl
j
arntzen
mani
advanc
continu
made
field
plantderiv
vaccin
plant
shown
capabl
express
multicompon
vaccin
oral
deliv
induc
thelper
cell
subset
respons
enabl
passiv
immun
furthermor
plantderiv
vaccin
shown
protect
challeng
target
host
increas
antigen
express
level
total
solubl
protein
obtain
transform
chloroplast
genom
view
find
plantderiv
vaccin
prove
valuabl
commod
world
health
system
howev
applic
studi
need
focu
optim
immun
strategi
investig
antigen
stabil
emerg
reemerg
diseas
increas
age
size
world
popul
threat
biolog
warfar
challeng
research
develop
product
arena
pharmaceut
industri
mani
effect
avenu
product
recombin
pharmaceut
protein
howev
main
challeng
lie
achiev
costeffect
product
larg
scale
past
five
year
potenti
use
plant
bioreactor
becom
well
establish
plant
system
offer
sever
advantag
econom
use
lowcost
input
light
water
miner
easili
adapt
largescal
oper
grow
plant
possess
minim
risk
contamin
potenti
human
pathogen
product
may
requir
purif
pharmaceut
produc
way
given
mucos
henc
simplifi
deliveri
decreas
overal
cost
plantderiv
pharmaceut
categor
three
area
antibodi
biopharmaceut
vaccin
plantderiv
antibodi
also
refer
plantibodi
extens
use
mani
area
includ
bioremedi
diseas
resist
plant
industri
purif
process
advanc
applic
plantibodi
howev
product
antibodi
medic
use
stoger
colleagu
provid
recent
review
plantderiv
antibodi
mani
report
biopharmaceut
express
plant
protein
divers
rang
applic
see
tabl
gener
howev
express
level
plantderiv
biopharmaceut
need
increas
commerci
product
accomplish
past
year
substanti
research
shown
plantderiv
vaccin
feasibl
commod
walmsley
arntzen
give
gener
descript
technolog
earli
develop
review
highlight
advanc
made
past
three
year
futur
direct
develop
plantderiv
vaccin
subunit
vaccin
compris
specif
macromolecul
induc
protect
immun
respons
pathogen
use
plant
express
antigen
use
vaccin
seen
continu
interest
past
year
wit
increas
number
report
transgen
plant
express
new
antigen
alter
express
previous
report
antigen
rang
differ
plant
vector
system
express
antigen
investig
summar
tabl
seedspecif
product
b
subunit
heatlabil
toxin
ltb
streatfield
et
al
achiev
ltb
express
level
reach
total
solubl
protein
tsp
two
separ
maiz
breed
program
increas
antigen
product
fivefold
tenfold
investig
chikwamba
et
al
regard
express
ltb
maiz
also
first
report
use
particl
bombard
product
plantderiv
vaccin
immunogen
demonstr
hepat
b
surfac
antigen
hbsag
protein
transmiss
gastroenter
coronaviru
tgev
human
immunodefici
viru
epitop
success
challeng
trial
result
immun
p
aeruginosa
epitop
epitop
foot
mouth
diseas
viru
fmdv
ltb
addit
antigen
express
plant
includ
respiratori
syncyti
viru
rsv
g
f
protein
protein
rotaviru
measl
viru
mv
hemagglutinin
h
protein
epitop
major
surfac
antigen
plasmodium
falciparum
although
immunogen
plantderiv
rsv
g
f
protein
measl
viru
h
protein
demonstr
anim
trial
immunogen
antigen
epitop
test
second
report
clinic
trial
carri
plantderiv
vaccin
appear
transgen
potato
express
norwalk
viru
capsid
protein
nvcp
control
tuberspecif
patatin
promot
oral
deliv
human
volunt
phase
iii
clinic
trial
total
number
volunt
ingest
transgen
potato
develop
signific
increas
specif
iga
antibodysecret
cell
develop
specif
serum
igg
develop
specif
stool
iga
although
increas
specif
serum
antibodi
modest
use
adjuv
improv
assembl
nvlike
particl
increas
dosag
recombin
protein
may
improv
nvcp
immunogen
see
updat
transform
plastid
genom
offer
sever
advantag
antigen
express
includ
highlevel
foreign
protein
express
remov
threat
gene
silenc
transgen
contain
owe
lack
pollen
transmiss
daniel
et
al
publish
first
report
plantderiv
vaccin
develop
chloroplast
transform
integr
unmodifi
cholera
toxin
b
subunit
ctb
code
region
chloroplast
genom
result
accumul
tsp
tobacco
leav
gm
gangliosidedepend
bind
assay
show
chloroplastsynthes
ctb
retain
abil
bind
intestin
membran
receptor
howev
immunogen
studi
perform
attempt
facilit
harvest
protein
antigen
express
tissuespecif
manner
maiz
kernel
tomato
fruit
seed
transgen
tobacco
target
major
glycoprotein
gb
human
cytomegaloviru
hcmv
transgen
tobacco
seed
previous
describ
investig
show
recombin
gb
almost
exclus
deposit
protein
storag
vesicl
matur
tobacco
seed
owe
minimalist
natur
subunit
vaccin
often
difficult
detect
recombin
protein
express
system
andor
ineffect
induc
mucos
immun
system
addit
protein
therefor
often
tabl
applic
biopharmaceut
produc
plant
employ
either
improv
detect
immunogen
subunit
vaccin
gil
et
al
du
santo
et
al
fuse
antigen
gene
encod
bglucuronidas
gu
increas
eas
detect
within
plant
express
system
instanc
transform
select
basi
gu
activ
gu
fusion
protect
epitop
canin
parvoviru
protect
epitop
fmdv
prove
immunogen
addit
mice
immun
gusfmdv
epitop
fusion
complet
protect
challeng
nativ
viru
cholera
toxin
ct
use
effect
target
protein
within
plantderiv
vaccin
nemchinov
et
al
describ
tobacco
mosaic
viru
tmv
express
vibrio
cholera
ctb
fusion
epitop
hepat
c
viru
hcv
tobacco
plant
inocul
recombin
tmv
produc
epitop
fuse
function
activ
pentamer
ctb
plantderiv
react
monoclon
antibodi
sera
individu
infect
viru
four
major
genotyp
hcv
intranas
immun
mice
crude
plant
extract
contain
recombin
elicit
antictb
serum
antibodi
serum
antibodi
specif
bound
hcvlike
particl
epitop
rotaviru
enterotoxin
protein
also
fuse
ctb
express
potato
express
multicompon
ct
fusion
vaccin
potato
expand
work
vaccin
consist
epitop
fusion
etec
fimbrial
antigen
fusion
compon
cta
associ
subunit
ctb
subunit
two
fusion
protein
assembl
cholera
holotoxinlik
structur
retain
enterocytebind
affin
oral
immun
mice
gener
detect
level
serum
mucos
antibodi
specif
nativ
antigen
elev
level
interferong
ifng
detect
immunogenchalleng
spleen
cell
immun
mice
indic
presenc
strong
thelper
cell
subset
immun
respons
three
plantsynthes
antigen
result
support
demonstr
signific
increas
lymphocyt
number
diarrheal
symptom
reduc
sever
durat
passiv
immun
mous
neonat
follow
rotaviru
challeng
paper
repres
first
report
multicompon
plantderiv
vaccin
work
also
demonstr
first
time
passiv
immun
plantderiv
vaccin
induct
immun
respons
oral
deliv
plantderiv
vaccin
vaccin
strategi
schedul
signific
effect
immun
respons
develop
lauterslag
et
al
investig
efficaci
potatoderiv
ltb
vaccin
mice
determin
oral
administr
plantderiv
ltb
elicit
system
local
iga
respons
parent
prime
anim
contrast
result
report
haq
et
al
mason
et
al
report
signific
specif
antibodi
respons
anim
show
protect
challeng
author
explan
includ
inadequ
immun
schedul
low
antigen
dose
low
antigen
immunogen
inabl
accur
detect
antibodi
interfer
tuber
materi
assay
tuber
materi
interfer
previou
studi
perform
potato
varieti
unsuccess
challeng
trial
indic
either
low
nonexist
antibodi
titer
investig
highlight
import
immun
regim
antigen
dosag
establish
immunogen
plantderiv
mv
h
protein
mice
trial
webster
et
al
optim
dose
plant
materi
requir
obtain
high
titer
mvspecif
neutral
antibodi
examin
boost
mv
h
dna
immun
plantderiv
vaccin
singledos
dna
inocul
follow
multipl
oral
deliv
plantderiv
booster
induc
significantli
greater
quantiti
mvneutral
antibodi
immun
dna
plantderiv
vaccin
alon
paper
report
first
demonstr
enhanc
immun
respons
primeboost
vaccin
strategi
combin
dna
vaccin
oral
deliv
plantderiv
vaccin
reliabl
method
need
quantifi
plantderiv
antigen
ensur
stabil
lee
et
al
perform
preliminari
stabil
studi
clover
plant
express
mannheimia
haemolytica
leukotoxin
fusion
protein
harvest
allow
dri
room
temperatur
ambient
humid
one
four
day
three
day
clover
tissu
retain
approxim
initi
fresh
weight
howev
signific
degrad
fusion
protein
observ
henc
fusion
protein
requir
refriger
stabil
cloverexpress
fusion
protein
induc
immun
respons
inject
rabbit
recogn
neutral
nativ
antigen
modifi
neutral
red
cytotox
assay
smith
et
al
perform
comprehens
stabil
studi
quantif
antigen
reactiv
hbsag
found
strongli
depend
ratio
deterg
cell
concentr
wv
sodium
ascorb
concentr
extract
buffer
improv
measur
level
monoclonalreact
antigen
deterg
also
influenc
antigen
stabil
cell
lysat
store
optimum
condit
stabil
maintain
least
one
month
wherea
excess
deterg
render
antigen
suscept
proteolyt
degrad
proteolysi
counteract
addit
skim
milk
protein
compon
stabil
antigen
two
month
also
alter
sodium
ascorb
concentr
buffer
ph
proport
hbsag
display
monoclonalreact
epitop
increas
although
antigen
stabil
investig
casebycas
basi
obviou
simpl
vitro
manipul
may
prove
valuabl
increas
immunogen
stabil
plantderiv
antigen
n
et
al
investig
minim
process
potatoderiv
rabbit
hemorrhag
diseas
viru
rhdv
vaccin
consist
gene
harvest
potato
peel
cut
piec
lyophil
powder
store
use
trial
within
three
month
collect
rabbit
prime
subcutan
boost
intramuscularli
extract
made
potato
powder
rabbit
immun
transgen
potato
elicit
specif
antibodi
respons
protect
challeng
virul
rdhv
evid
plant
express
system
lead
improv
manufactur
deliveri
vaccin
hand
studi
proven
plant
capabl
express
mani
differ
antigen
demonstr
immunogen
test
shown
provid
protect
model
target
anim
often
state
need
increas
antigen
express
level
plant
howev
target
express
plant
breed
allevi
problem
preliminari
investig
antigen
stabil
process
optim
immun
strategi
perform
howev
need
indepth
studi
individu
antigen
plantderiv
vaccin
use
commod
recent
concern
rais
regard
regul
plantderiv
vaccin
safeti
food
chain
contamin
pharmaceut
reason
initi
concept
edibl
fooddeliv
vaccin
need
develop
inexpens
plantderiv
mucos
vaccin
regul
prescript
releas
like
transgen
plant
use
modern
agricultur
product
within
unit
state
two
entiti
current
regul
plantderiv
pharmaceut
us
depart
agricultur
usda
food
drug
administr
fda
usda
current
regul
locat
contain
transgen
plant
express
pharmaceut
wherea
fda
ensur
qualiti
assur
qualiti
control
fda
guarante
qualiti
assur
qualiti
control
standard
maintain
product
prepar
materi
ensur
safeti
efficaci
materi
human
administr
fda
also
determin
rel
risk
progress
plantderiv
pharmaceut
licensur
phase
clinic
trial
monitor
recent
fda
releas
first
draft
regul
product
plantderiv
pharmaceut
regulatori
environ
us
evolv
encourag
safe
yet
rapid
commerci
plantderiv
pharmaceut
recent
develop
plantderiv
vaccin
product
report
bring
technolog
ever
closer
graduat
research
develop
phase
coevolut
plantderiv
vaccin
technolog
product
regul
ensur
prototyp
vaccin
close
becom
use
commod
addit
human
clinic
trial
plantderiv
vaccin
report
august
transgen
spinach
express
epitop
rabi
viru
glycoprotein
g
protein
nucleoprotein
n
protein
fuse
coat
protein
cp
alfalfa
mosaic
viru
almv
oral
deliv
human
volunt
five
volunt
previous
immun
convent
rabi
vaccin
three
five
volunt
previous
immun
convent
vaccin
five
nine
initi
naiv
individu
show
signific
specif
antibodi
respons
rabi
viru
none
control
volunt
sampl
show
signific
elev
rabiesspecif
antibodi
seven
day
complet
feed
regim
nine
initi
naiv
volunt
given
dose
convent
rabi
viru
vaccin
three
individu
show
rabi
viru
neutral
antibodi
none
five
control
show
antibodi
although
neutral
antibodi
detect
immun
commerci
vaccin
clear
indic
potenti
plantderiv
rabi
vaccin
act
supplementari
oral
booster
rabi
vaccin
